Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CWP-0403 vs Sitagliptin in T2DM on Metformin
NCT01529541Phase 3Completed
- Sponsor
- JW Pharmaceutical Corporation
- Start
- May 2011
- Primary completion
- May 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of anagliptin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by JW Pharmaceutical Corporation. Primary endpoint: Change in HbA1c from baseline at 24 weeks. Started May 2011; status: completed.
02
Drugs
anagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01529541.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01529541.